News | December 22, 2011

ESC Calls for Studies Exploring Readmissions to Hospital Following PCI


December 22 2011 — A recent United States study on the importance of measuring rates of rehospitalization following percutaneous coronary intervention (PCI) has drawn the attention of the European Society of Cardiology (ESC). The research, published in the JACC Cardiovascular Interventions, represents one of the first studies to explore PCI readmissions. According to ESC, it highlights the need for similar studies to be initiated across Europe to improve patient care.

In the study, Edward Hannan, M.D., and colleagues from the School of Public Health at the University of New York, recorded hospital readmissions for 40,093 patients from New York State. All patients underwent their first PCI procedure between Jan. 1 and Nov. 30, 2007. The retrospective review found a total of 15.6 percent (6,254) of PCI patients were readmitted within 30 days; further analysis revealed that 20.6 percent (1,285) of these readmissions were “staged.” In staging, cardiologists treat the culprit lesion responsible for the initial admission; they then plan for patients to return to the hospital at a future date for treatment of additional lesions.

“Currently we’ve absolutely no idea of the number of patients in Europe who need readmission to hospitals after PCI,” said Prof. Eric Van Belle, an ESC spokesperson from the University of Lille, France. But the U.S. finding that 12.4 percent of PCI patients need to return for unplanned readmissions (not involving staging), he added, was much higher than predicted; to him, this highlighted the need for improvements in care.

 “To allow us to both prevent readmissions by tailoring care to individual patients and produce guidelines around which patients require staging, we need to gain a better handle on data in Europe,” Van Belle said.

Nevertheless, the question remains whether Europe has the infrastructure to identify patients who are likely to be readmitted to multiple hospitals. In the U.S. study, investigators acknowledged that principle diagnoses such as “chronic ischemic heart disease,” “atherosclerosis” and “chest pain” were not specific enough to determine the real reasons for admissions. This left doubts over whether the readmission had been necessitated by a complication of the index procedure or some separate event.

“Achieving a better understanding of the reasons why patients need unplanned admissions would help cardiologists learn how to target interventions to patients at greatest risk of complications,” said ESC spokesperson Prof. Hans Erik Bøtker, from Aarhus University, Skejby, Denmark.

Increased knowledge would also enable hospitals to be adequately reimbursed for the care. “Payments to hospitals could be adjusted to take into account factors such as co-morbidities that are likely to require additional care to prevent repeat hospitalization. The introduction of such systems would remove incentives for hospitals to discharge patients early,” said Bøtker.

The different health care reimbursement systems used in European countries, said Van Belle, influence whether hospitals offer “staged” readmissions. In some countries, hospitals are reimbursed with one fee for a fixed time period regardless of the number of individual procedures or different admissions; while in other countries a separate fee is paid for each admission. The former approach discourages use of staged procedures, while the later serves to encourage them. Both systems, argued Van Belle, can fail to take into account the clinical needs of individual patients.

“For each patient, a risk benefits analysis needs to be undertaken. For most people single procedures (where all the lesions are treated at the same time) carry less overall risks than multiple procedures. However, in certain circumstances when a great number of lesions need to be treated, staged care may be necessary to reduce excessive exposure to radiation,” said Van Belle.

Clearly, he added, evidence-based guidelines are needed to identify the patient groups who would benefit most from staged procedures. “We need to base our decisions on clinical evidence rather than being swayed by financial gain,” said Van Belle.

For more information: www.escardio.org


Related Content

News | Cath Lab

December 20, 2023 — Jason R. McCarthy, Ph.D., associate professor of biomedical research and translational medicine and ...

Home December 20, 2023
Home
News | Cath Lab

October 26, 2023 — Royal Philips, a global leader in health technology, announced the latest results demonstrating the ...

Home October 26, 2023
Home
News | Cath Lab

October 25, 2023 — Shockwave Medical, Inc., a pioneer in the development and commercialization of transformational ...

Home October 25, 2023
Home
News | Cath Lab

October 20, 2023 — Over the coming days, Philips will be presenting its latest solutions in cardiology and new late ...

Home October 20, 2023
Home
News | Cath Lab

October 16, 2023 — GE HealthCare (Nasdaq: GEHC) announced US FDA 510(k) clearance of Allia IGS Pulse - the latest ...

Home October 16, 2023
Home
News | Cath Lab

October 16, 2023 — Shimadzu Medical Systems USA, a subsidiary of Shimadzu Corporation, announced the first U.S ...

Home October 16, 2023
Home
News | Cath Lab

September 13, 2023 — A diagnostic test, first offered in the United States at University Hospitals (UH) Harrington Heart ...

Home September 13, 2023
Home
News | Cath Lab

August 2, 2023 — Teleflex Incorporated, a leading global provider of medical technologies, announced the U.S Food and ...

Home August 02, 2023
Home
News | Cath Lab

July 13, 2023 — Mount Sinai Queens announced the opening of a new cardiac catheterization lab that will provide rapid ...

Home July 13, 2023
Home
News | Cath Lab

June 21, 2023 — Royal Philips, a global leader in health technology, announced it has teamed up with BIOTRONIK (Lake ...

Home June 21, 2023
Home
Subscribe Now